KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

CRISPR Therapeutics AG (CRSP) EBITDA Margin (2016 - 2025)

CRISPR Therapeutics AG's EBITDA Margin history spans 11 years, with the latest figure at 15136.34% for Q4 2025.

  • For Q4 2025, EBITDA Margin fell 1500736.0% year-over-year to 15136.34%; the TTM value through Dec 2025 reached 16484.84%, down 1550311.0%, while the annual FY2025 figure was 16484.84%, 1550311.0% down from the prior year.
  • EBITDA Margin for Q4 2025 was 15136.34% at CRISPR Therapeutics AG, down from 11866.82% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 84.27% in Q2 2021 and bottomed at 1732650.0% in Q4 2022.
  • The 5-year median for EBITDA Margin is 15448.3% (2021), against an average of 117090.62%.
  • The largest annual shift saw EBITDA Margin crashed -173152166bps in 2022 before it surged 173269873bps in 2023.
  • A 5-year view of EBITDA Margin shows it stood at 1128.34% in 2021, then tumbled by -153457bps to 1732650.0% in 2022, then soared by 100bps to 48.73% in 2023, then tumbled by -365bps to 128.98% in 2024, then tumbled by -11635bps to 15136.34% in 2025.
  • Per Business Quant, the three most recent readings for CRSP's EBITDA Margin are 15136.34% (Q4 2025), 11866.82% (Q3 2025), and 23390.47% (Q2 2025).